Anti-P53 antibodies in Brazilian brain tumor patients

Genetics and Molecular Research

Volumn 2, Issue 2, 2003, Pages 185-190

  Fonseca, Renata Fragelli ^a   Kawamura, Márcia Tie ^b   Oliveira, José Antônio ^b   Teixeira, Anselmo ^b   Alves, Gilda ^b   Da Costa Carvalho, María Da Glória ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Anti p53 antibodies; Glioma; Western blotting

Indexed keywords

PLASMA PROTEIN; PROTEIN ANTIBODY; PROTEIN P53; PROTEIN P53 ANTIBODY; UNCLASSIFIED DRUG; CANCER ANTIBODY; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BLOOD SAMPLING; BRAIN TUMOR; BRAZIL; CANCER GRADING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; MALE; PLASMA; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; WESTERN BLOTTING; BLOOD; CHILD; GENETICS; GLIOMA; IMMUNOLOGY; MIDDLE AGED; MUTATION; PRESCHOOL CHILD; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, NEOPLASM; BLOTTING, WESTERN; BRAIN NEOPLASMS; BRAZIL; CHILD; CHILD, PRESCHOOL; FEMALE; GENES, P53; GLIOMA; HUMANS; MALE; MIDDLE AGED; MUTATION; RECOMBINANT PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 2342431495     PISSN: 16765680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Angelopoulou, K. and Diamandis, E.P. (1997). Detection of the TP53 tumour suppressor gene product and p53 auto-antibodies in the ascites of women with ovarian cancer. Eur. J. Cancer 33: 115-121.
2. Anker, L., Ohgaki, H., Ludeke, B., Hermann, H.-D., Kleihues, P. and Westhpal, M. (1993). p53 protein accumulation and gene mutations in human glioma cell line. Int. J. Cancer 55: 982-987.
3. Bradford, M.M. (1976). A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Bioch. 72: 248-254.
4. CBTRUS (2000). Primary Brain Tumors in the United States Statistical Report. Central Brain Tumor Registry of the United States. Chicago, IL, USA.
5. Crawford, L.V., Piw, D.C. and Bulbrook, R.D. (1982). Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int. J. Cancer 30: 403-408.
6. Davidoff, A.M., Iglehart, J.D. and Marks, J.R. (1992). Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc. Natl. Acad. Sci. USA 89: 3439-3442.
7. Kleihues, P., Burger, P.C. and Scheithauer, B.W. (1993). Histological typing of tumors of the central nervous system. WHO International Histological Classification of Tumours. Springer-Verlag, Berlin-Heidelberg, Germany.
8. Laemmli, U.K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
9. Levesque, M.A., D'Costa, M. and Diamandis, E.P. (1996). p53 protein is absent from the serum of patients with lung cancer. Br. J. Cancer 74: 1434-1440.
10. Linzer, D.I.H. and Levine, A.J. (1979). Characterization of a 54K dalton cellular SV40 tumor antigen present in SV 40 cells and uninfected embryonal carcinoma cells. Cell 17: 43-52.
11. Maxwell, M., Galanopulos, T., Neville-Golden, J. and Antoniades, H. (1992). Effect of the expression of transforming growth factor B-2 in primary human glioblastoma on immunosuppression and loss of immune surveillance. J. Neurosurg. 76: 799-804.
12. Rainov, N.G., Dobberstein, K.U., Fittkan, M., Bahn, H., Holzhausen, H.J., Gantchev, L. and Burket, W. (1995). Absence of p53 autoantibodies in sera from glioma patients. Clin. Cancer Res. 1: 775-781.
13. Rasheed, B.K., Wiltshire, R., Bigner, S. and Bigner, D. (1999). Molecular pathogenesis of malignant gliomas. Curr. Opin. Oncol. 11: 162-167.
14. Sambrook, J., Fristsch, E.P. and Maniats, T. (1989). Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.
15. Shibata, Y., Kotanagi, H., Andoh, H., Koyama, K., Itoh, H. and Kudo, S. (1996). Detection of circulating anti-p53 antibodies in patients with colorectal carcinoma and the antibody's relation to clinical factors. Dis. Colon Rectum 39: 1269-1274.
16. Sidransky, D. and Hollstein, M. (1996). Clinical implications of p53 gene. Ann. Rev. Med. 47: 285-301.
17. Soussi, T. (2000). P53 antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 60: 1777-1788.
18. Tilkin, A., Lubin, R., Soussi, T., Lazar, V., Janin, N., Mathieu, M., Carlu, C., Roy, M., Kayibanda, M., Bellet, D., Guillet, J. and Paillerets, B. (1995). Primary proliferative T cell response to wild type p53 protein in patients with breast cancer. Eur. J. Immunol. 25: 1765-1769.
19. Towbin, H., Staehelin, T. and Gordon, J. (1979). Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA 76: 4350-4354.
20. Volkman, M., Muller, M., Hoffmann, W.J., Meyer, M., Hagelstein, J., Rath, U., Kommerele, B., Zengtraf, H. and Gale, P.R. (1993). The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the alpha-fetoprotein status. Hepatology 18: 559-565.
21. Weller, M., Borneman, A., Stander, M., Schabet, M., Dichgans, J. and Meyermann, R. (1998). Humoral immune response to p53 in malignant glioma. J. Neurol. 245: 169-172.